Evidence map›Paper›PMID 35579509›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023

Transfusing Convalescent Plasma as Post-Exposure Prophylaxis Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Double-Blinded, Phase 2 Randomized, Controlled Trial.

Shmuel Shoham, Evan M Bloch, Arturo Casadevall, Daniel Hanley, Bryan Lau, Kelly Gebo, Edward Cachay, Seble G Kassaye, James H Paxton, Jonathan Gerber and 46 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04323800 (Convalescent Plasma to Stem Coronavirus), which is not on this map. Cited by 31 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 5 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04323800 phase2completednot on this map

Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19

TypeinterventionalSponsorJohns Hopkins UniversityRan2020 to 2021Enrolled180ConditionsCoronavirus, ConvalescenceArmsAnti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 5 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Convalescent Plasma for Immunocompromised Patients.Current topics in microbiology and immunology · 2025
    Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

56 authors at 20 institutions in 1 country.

Shmuel ShohamDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Evan M BlochDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Arturo CasadevallDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Daniel HanleyDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Bryan LauDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Kelly GeboDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Edward CachayDepartment of Medicine, Division of Infectious Diseases, University of California, San Diego, San Diego, California, USA.
Seble G KassayeDivision of Infectious Diseases/Department of Medicine, Georgetown University Medical Center, Washington D.C, USA.
James H PaxtonDepartment of Emergency Medicine, Wayne State University, Detroit, Michigan, USA.
Jonathan GerberDepartment of Medicine, Division of Hematology and Oncology, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Adam C LevineDepartment of Emergency Medicine, Rhode Island Hospital/Brown University, Providence, Rhode Island, USA.
Arash NaeimDepartment of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA.
Judith CurrierDepartment of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA.
Bela PatelDepartment of Medicine, Division Critical Care Medicine, University of Texas Health, Houston, Texas, USA.
Elizabeth S AllenDepartment of Pathology, University of California, San Diego, San Diego, California, USA.
Shweta AnjanDepartment of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Lawrence AppelDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Sheriza BakshDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Paul W BlairDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Anthony BowenDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Patrick BroderickDepartment of Emergency Medicine, Danbury Hospital, Danbury, Connecticut, USA.
Christopher A CaputoDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Valerie CluzetVassar Brothers Medical Center, Nuvance Health, Poughkeepsie, New York, USA.
Marie Elena CordiscoOffice of Clinical Trials, Nuvance Health, University of Vermont, Danbury, Connecticut, USA.
Daniel CruserDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Stephan EhrhardtDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Donald ForthalDepartment of Medicine, Division of Infectious Diseases, University of California, Irvine, Irvine, California, USA.
Yuriko FukutaDepartment of Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA.
Amy L GawadDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Thomas GniadekDepartment of Pathology, Northshore University Health System, Evanston, Illinois, USA.
Jean HammelDepartment of Emergency Medicine, Norwalk Hospital, Norwalk, Connecticut, USA.
Moises A HuamanDepartment of Medicine, Division of Infectious Diseases, University of Cincinnati, Cincinnati, Ohio, USA.
Douglas A JabsDepartment of Ophthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Anne JedlickaDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Nicky KarlenMosaic Consulting Ltd., Israel.
Sabra KleinDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Oliver LaeyendeckerDivision of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, Maryland, USA.
Karen LaneDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nichol McBeeDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Barry MeisenbergDepartment of Medicine, Luminis Health, Annapolis, Maryland, USA.
Christian MerloDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Giselle MosnaimDivision of Allergy and Immunology, Department of Medicine, Northshore University Health System, Evanston, Illinois, USA.
Han-Sol ParkDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Andrew PekoszDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Joann PetriniOffice of Clinical Trials, Nuvance Health, University of Vermont, Danbury, Connecticut, USA.
William RauschOffice of Clinical Trials, Nuvance Health, University of Vermont, Danbury, Connecticut, USA.
David M ShadeDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Janna R ShapiroDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
J Robinson SingletonDepartment of Neurology, University of Utah, Salt Lake City, Utah, USA.
Catherine SutcliffeDepartment of Epidemiology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
David L ThomasDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Anusha YaravaDepartment of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Martin ZandDepartment of Medicine, University of Rochester, Rochester, New York, USA.
Jonathan M ZenilmanDepartment of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Aaron A R TobianDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
David J SullivanDepartment of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of Vermont · USNorthShore University HealthSystem · USUniversity of California, Los Angeles · USUniversity of California, San Diego · USBaylor College of Medicine · USDanbury Hospital · USGeorgetown University Medical Center · USNational Institute of Allergy and Infectious Diseases · USNorwalk Hospital · USRhode Island Hospital · USThe University of Texas Health Science Center at Houston · USUniversity of California, Irvine · USUniversity of Cincinnati · USUniversity of Massachusetts Chan Medical School · USUniversity of Miami · USUniversity of Rochester · USUniversity of Utah · USVassar Brothers Medical Center · US

Funding

Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
Johns Hopkins-Tufts Trial Innovation Center HEAL Pain ERN SupplementU24TR001609 · NCATS · JOHNS HOPKINS UNIVERSITY · PI HANLEY, DANIEL F · 2016 to 2022
$36.3M
University of California Health Participation in the National COVID Cohort Collaborative (N3C)UL1TR001414 · NCATS · UNIVERSITY OF CALIFORNIA-IRVINE · PI COOPER, DAN M, VILAIN, ERIC J. · 2015 to 2023
$35.1M
Conjugate vaccines for prevention and treatment of cryptococcosis - COVID-19 Revision SupplementR01AI152078 · NIAID · JOHNS HOPKINS UNIVERSITY · PI CASADEVALL, ARTURO · 2020 to 2024
$5.1M
Epidemiologic and Immunologic Investigations of SARS-CoV-2 (COVID-19) InfectionsZIAAI001286 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI QUINN, THOMAS · 2020 to 2023
$349k
NCATS NIH HHS U24 TR001609NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001414NIAID NIH HHS R01 AI152078
6 · The paper itself

Abstract

backgroundThe efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.

methodsThis double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed coronavirus disease 2019 (COVID-19) in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was new SARS-CoV-2 infection.

resultsIn total, 180 participants were enrolled; 87 were assigned to CCP and 93 to control plasma, and 170 transfused at 19 sites across the United States from June 2020 to March 2021. Two were excluded for screening SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) positivity. Of the remaining 168 participants, 12/81 (14.8%) CCP and 13/87 (14.9%) control recipients developed SARS-CoV-2 infection; 6 (7.4%) CCP and 7 (8%) control recipients developed COVID-19 (infection with symptoms). There were no COVID-19-related hospitalizations in CCP and 2 in control recipients. Efficacy by restricted mean infection free time (RMIFT) by 28 days for all SARS-CoV-2 infections (25.3 vs 25.2 days; P = .49) and COVID-19 (26.3 vs 25.9 days; P = .35) was similar for both groups.

conclusionsAdministration of high-titer CCP as post-exposure prophylaxis, although appearing safe, did not prevent SARS-CoV-2 infection. CLINICAL TRIALS REGISTRATION: NCT04323800.

Indexed as

COVID-19SARS-CoV-2AdolescentAdultCOVID-19 SerotherapyDouble-Blind MethodHumansImmunization, PassivePost-Exposure Prophylaxisconvalescent plasmaCOVID-19post-exposure-prophylaxisSARS-CoV-2transfusion

Identifiers

PMID35579509
PMCPMC9129191
OpenAlexW4280548373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.